LAMATTINA JOHN L 4
4 · LIGAND PHARMACEUTICALS INC · Filed Dec 2, 2024
Insider Transaction Report
Form 4
LAMATTINA JOHN L
Director
Transactions
- Exercise/Conversion
Common Stock
2024-11-27$52.30/sh+2,406$125,834→ 31,921 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-11-27−2,406→ 0 totalExercise: $52.30Exp: 2025-04-24→ Common Stock (2,406 underlying) - Sale
Common Stock
2024-11-27$123.65/sh−2,406$297,502→ 29,515 total
Footnotes (1)
- [F1]This Option was previously reported as a Grant of 2,754 shares on April 24, 2015, which vested in full on April 24, 2016, at an exercise price of $89.7500 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.